Related Experiment Video
Updated: Aug 11, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Phenoxodiol: isoflavone analog with antineoplastic activity
Toni K Choueiri1, Robert Wesolowski, Tarek M Mekhail
1Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, R-35, Cleveland, OH 44195, USA. choueit@ccf.org
Abstract:
Phenoxodiol, a synthetic analog of the plant isoflavone genistein, represents a new generation of oncology drugs acting as multiple signal transduction regulators. Phenoxodiol exerts its effect mainly by the induction of apoptosis through multiple mechanisms resulting in degradation of antiapoptotic proteins, with increased levels being linked to chemoresistance in tumor cells. Preclinical studies with this agent showed promising anticancer activity leading to a potential role in the treatment of a wide range of solid and hematologic cancers. Early clinical studies, especially in chemotherapy-resistant ovarian cancer, showed minimal toxicity with minor antitumor activity. Hormone-refractory prostate cancer is another promising area in which phenoxodiol is being actively tested. Studies are ongoing to define the optimal use of this novel anticancer agent.
Insights
Phenoxodiol, a novel oncology drug, induces apoptosis to combat cancer by degrading antiapoptotic proteins. Ongoing studies explore its potential in treating various cancers, including ovarian and prostate cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Phenoxodiol is a synthetic analog of genistein, acting as a multi-signal transduction regulator.
- It targets antiapoptotic proteins, crucial in chemoresistance, via apoptosis induction.
- Preclinical studies indicate broad anticancer potential against solid and hematologic malignancies.
Purpose of the Study:
- To evaluate the efficacy and safety of phenoxodiol in cancer treatment.
- To explore its role in chemotherapy-resistant cancers.
- To define optimal therapeutic strategies for phenoxodiol.
Main Methods:
- Preclinical investigations of anticancer activity.
- Early-phase clinical trials in ovarian and prostate cancer patients.
- Assessment of toxicity and antitumor activity.
Main Results:
- Preclinical studies demonstrated promising anticancer activity.
- Early clinical trials in ovarian cancer showed minimal toxicity and minor antitumor effects.
- Phenoxodiol is being actively investigated in hormone-refractory prostate cancer.
Conclusions:
- Phenoxodiol shows potential as a novel anticancer agent targeting multiple signaling pathways.
- Further research is required to establish its optimal clinical application and efficacy in various cancer types.
- Ongoing studies aim to define its role in treating resistant and advanced cancers.
More Related Videos
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Antifungal Agents
Antiviral Nucleoside Inhibitors